Mertens W C, Bramwell V
London Regional Cancer Centre, Ontario, Canada.
Curr Opin Oncol. 1994 Jul;6(4):384-90. doi: 10.1097/00001622-199407000-00010.
Steady progress has been made in the identification of genetic alterations and prognostic factors in osteosarcoma. Imaging studies continue to be employed not only for preoperative staging, but to quantify factors such as tumor bulk and tumor response to neoadjuvant chemotherapy. Although there have been no major refinements of local or systemic therapy, continuing research into novel agents (eg, liposomal muramyl, tripeptide phosphatidylethanolamine, and antisense oligonucleotides to insulin-like growth factor receptors) hold promise for new therapies for this disease in the future.
骨肉瘤基因改变和预后因素的识别已取得稳步进展。影像学研究不仅继续用于术前分期，还用于量化肿瘤大小和肿瘤对新辅助化疗的反应等因素。尽管局部或全身治疗没有重大改进，但对新型药物（如脂质体胞壁酰二肽、三肽磷脂酰乙醇胺和胰岛素样生长因子受体反义寡核苷酸）的持续研究有望为该病未来带来新的治疗方法。
